Alnylam Pharmaceuticals, Inc.  

(Public, NASDAQ:ALNY)   Watch this stock  
Find more results for ALNY
67.78
-2.16 (-3.09%)
Sep 30 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 67.06 - 70.38
52 week 49.96 - 110.75
Open 70.26
Vol / Avg. 857,140.00/513,564.00
Mkt cap 5.14B
P/E     -
Div/yield     -
EPS -4.24
Shares 85.72M
Beta 2.39
Inst. own 89%
Nov 7, 2016
Q3 2016 Alnylam Pharmaceuticals Inc Earnings Release (Estimated) - 4:00PM EST - Add to calendar
Sep 28, 2016
Alnylam Pharmaceuticals Inc at Leerink Partners Rare Disease & IO Roundtable Series - Webcast
Sep 16, 2016
Alnylam Pharmaceuticals Inc at Bank of America Merrill Lynch Healthcare Conference - Webcast
Sep 14, 2016
Alnylam Pharmaceuticals Inc at Morgan Stanley Global Healthcare Conference
Sep 13, 2016
2016 RNAi Roundtable: ALN-AS1 for the Treatment of Acute Hepatic Porphyrias Call
Aug 31, 2016
2016 RNAi Roundtable: ALN-CC5 for the Treatment of Complement-Mediated Diseases Call - Webcast
Aug 22, 2016
2016 RNAi Roundtable: Fitusiran for the Treatment of Hemophilia and Rare Bleeding Disorders Corporate Call - Webcast
Aug 10, 2016
Alnylam Pharmaceuticals Inc at Canaccord Genuity Growth Conference - Webcast
Aug 4, 2016
Q2 2016 Alnylam Pharmaceuticals Inc Earnings Call - Webcast
Aug 4, 2016
Q2 2016 Alnylam Pharmaceuticals Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q2 (Jun '16) 2015
Net profit margin -1034.89% -705.83%
Operating margin -1061.55% -720.27%
EBITD margin - -673.91%
Return on average assets -26.79% -23.52%
Return on average equity -31.61% -26.36%
Employees 369 -
CDP Score - -

Address

300 3rd St
CAMBRIDGE, MA 02142-1103
United States - Map
+1-617-5518200 (Phone)
+1-617-5518101 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is engaged in developing therapeutics based on ribonucleic acid (RNA) interference (RNAi). It is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate strategy for delivery of small interfering RNAs (siRNAs). Its pipeline of investigational RNAi therapeutics focuses in three Strategic Therapeutic Areas (STArs): Genetic Medicines; Cardio-Metabolic Disease, and Hepatic Infectious Disease. Its Genetic medicines include Patisiran (ALN-TTR02), Revusiran (ALN-TTRsc), Fitusiran (ALN-AT3), ALN-CC5, ALN-AS1, and additional genetic programs, including ALN-AAT, ALN-GO1 and ALN-TMP. Products for Cardio-Metabolic Disease STAr include ALN-PCSsc and other cardio-metabolic disease programs ALN-AC3 and ALN-ANG targeting Angiopoetin-like 3 (ANGPTL3). Products for Hepatic Infectious Disease STAr include ALN-HBV, ALN-HDV and ALN-PDL. It also owns Enhanced Stabilization Chemistry, GalNAc-conjugate delivery platform.

Officers and directors

Michael W. Bonney Independent Chairman of the Board
Age: 57
Bio & Compensation  - Reuters
Barry E. Greene President
Age: 52
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
John M. Maraganore Ph.D. Chief Executive Officer, Director
Age: 53
Bio & Compensation  - Reuters
David-Alexandre Gros M.D. Principal Financial Officer, Chief Business Officer, Senior Vice President
Age: 44
Bio & Compensation  - Reuters
Yvonne Greenstreet Chief Operating Officer, Executive Vice President
Age: 53
Bio & Compensation  - Reuters
Akshay K. Vaishnaw M.D. Ph.D. Executive Vice President - Research and Development ,Chief Medical Officer
Age: 53
Bio & Compensation  - Reuters
.. Bartlett Keating Senior Vice President - General Counsel, Secretary
Age: 61
Bio & Compensation  - Reuters
Michael P. Mason Principal Accounting Officer, Vice President, Treasurer
Age: 41
Bio & Compensation  - Reuters
Dennis A. Ausiello M.D. Independent Director
Age: 70
Bio & Compensation  - Reuters
John K. Clarke Independent Director
Age: 62
Bio & Compensation  - Reuters